Brief: Respiratorius Announces Positive Results For RES030-085

Respiratorius AB (publ)

25/06/2019 14:17

June 25 (Reuters) - Respiratorius AB (publ)  RESPS.TE :
    * BRONCHODILATOREFFECT SHOWN IN VIVO FOR THE NEW RES030-085
SUBSTANCE WITHIN RESP9000
    * ANNOUNCES POSITIVE RESULTS FROM AIRWAY STUDY IN ANIMAL
MODEL
WITH PATENTED CANDIDATE SUBSTANCE RES030-085 FOR TREATMENT OF
COPD AND SEVERE ASTHMA
    * EXPERIMENTS SHOWED THAT RES030-085 HAS A CLEAR AND
STATISTICALLY
SIGNIFICANT BRONCHODILATOR EFFECT IN RATS COMPARED TO CONTROL
GROUP
    * TRIALS DID NOT RESULT IN ANY MEASURED OR OBSERVED ADVERSE
REACTIONS AT EFFECTIVE DOSE OF RES030-085
    * FURTHERMORE, PRELIMINARY CHARACTERIZATION STUDIES OF
CHEMICAL
STRUCTURE HAVE SHOWN THAT RES030-085 HAS A HIGH LIKELIHOOD OF
SUCCESSFUL FORMULATION AS AN INHALED DRUG
    * PRELIMINARY CHARACTERIZATION STUDIES OF CHEMICAL STRUCTURE
HAVE
SHOWN THAT RES030-085 HAS A HIGH LIKELIHOOD OF SUCCESSFUL
FORMULATION AS AN INHALED DRUG

Source text for Eikon:  ID:nWkrQM5vB 
Further company coverage:  RESPS.TE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))